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Accepted 3 October 2014Context and Objective. Based on evidence that leptin and adiponectin are removed from
circulation primarily by the kidney, we designed a study to examine the longitudinal
changes of these adipokines during the first week after kidney transplantation (KTx) and to
test the hypothesis that higher levels of leptin and/or adiponectin could be early biomarkers
of delayed graft function (DGF = dialysis requirement during the first post-transplant week)
and acute rejection.
Study Design. Repeated-measures prospective study.
Material and Methods. Forty consecutive adult patients with end-stage renal disease who
were undergoing KTx. Leptin and adiponectin were measured in blood samples that were
collected before (day-0) and after KTx (days-1, 2, 4 and 7). Linear mixed-models, receiver
operating characteristic and area under curve (AUC-ROC) were used.
Results. At post-transplant day-1, leptinemia and adiponectinemia declined 43% and 47%,
respectively. At all times studied after KTx, the median leptin levels were significantly higher
in patients developingDGF (n = 18), but not adiponectin levels. Shortly after KTx (day-1), leptin
values were significantly higher in DGF recipients in contrast to patients with promptly
functioning kidneys, approximately two times higher when controlling for gender and BMI.
The leptin reduction rate between pre-tranplant and one-day after KTx moderately predicted
DGF (AUC = 0.73). On day-1, serum leptin predicted DGF (AUC-ROC = 0.76) with a performance
slightly better than serum creatinine (AUC-ROC = 0.72), even after correcting for BMI
(AUC-ROC = 0.73). Separating this analysis by gender showed that the performance of leptin
in predicting DGF for male gender (AUC-ROC = 0.86) improved.Keywords:
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203M E T A B O L I S M C L I N I C A L A N D E X P E R I M E N T A L 6 4 ( 2 0 1 5 ) 2 0 2 – 2 0 7Conclusions. Kidney graft function is an independent determinant of leptin levels, but not
of adiponectin. Leptin levels at day-1 slightly outperformed serum creatinine in predicting
the occurrence of DGF, and more accurately in male gender. No significant association was
detected with acute rejection.
© 2015 Elsevier Inc. All rights reserved.1. Introduction
White adipose tissue is now recognized as a multifunctional
organ [1]. In addition to its central role in lipid storage, white
adipose tissue has a major endocrine function by synthesiz-
ing a multitude of protein cytokines termed adipokines.
Leptin and adiponectin (ADPN) are two adipokines that elicit
generally opposing pro-inflammatory and anti-inflammatory
effects [1–4]. In chronic kidney disease, the clinical signifi-
cance and prognostic implications of leptin and ADPN are not
well understood. Patients with chronic kidney disease have
increased circulating levels of both adipokines that may result
from an increase in their systemic production and/or decrease
in their renal clearance [5–13].
The contribution of the kidney in the biodegradation and
elimination of leptin and adiponectin appears to be confirmed
in studies conducted in kidney transplantation (KTx),where the
circulating levels of these adipokines decrease after successful
transplantation [14–19]. Based on the growing evidence that
leptin and ADPN are removed from the circulation primarily by
the kidney, we designed the present study to examine the
longitudinal changes of these two adipokines during the first
week post-transplant and test the hypothesis that delayed graft
function (DGF)would be associatedwithhigher plasma levels of
leptin and due to their impaired clearance by the kidney.
Therefore, we hypothesized that higher levels of leptin and/or
ADPN could serve as early biomarkers of DGF (defined as
dialysis requirementwithin the firstweek after KTx). Due to the
role of leptin in the immune system [9,20–24], the performance
of leptin in predicting acute transplant rejection and allo-
immunity was also assessed.2. Patients and Methods
2.1. Study Design and Patient Population
Consecutive patients with end-stage renal disease who were
undergoing living or deceased donor KTx between December
2010 and May 2011 were prospectively enrolled. Patients
under the age of 18 or who required multiorgan transplants
were not included. The Institutional Review Board of Centro
Hospitalar do Porto approved the study. Each participant
provided informed consent.
2.2. Laboratory Analyses
Blood samples were collected as follows: 3–6 h prior to
transplant surgery (pre-transplant); on the followingmorning,
approximately 8–12 h after graft reperfusion (day-1); and then
on the second (day-2), fourth (day-4) and seventh days (day-7)
after transplant, for a total of five samples per patient.Serum levels of leptin and ADPN were measured by ELISA
based on the direct sandwich technique using kits from
Mercodia, Sweden. Standard values of leptin for normal weight
people were 2–5.6 ng/mL for male and 3.7–11.1 ng/mL for
female. Expected normal values for ADPN were 5–300 ng/mL.
2.3. Definitions
Delayed graft function was defined by the need for dialysis
during the first week after KTx.
Acute rejection was defined as either biopsy-proven rejec-
tion or anti-rejection treatment without biopsy.
Leptin/BMI ratio was calculated to measure the leptin level
while controlling for the BMI contribution.
2.4. Statistical Analyses
The distributions of continuous variables were analyzed
using Kolmogorov–Smirnov test and variables showing a
positively skewed distribution (leptin and SCr) were natural
logarithm transformed prior to parametric test analyses.
Statistical analysis was conducted in three steps. First, a
cross-sectional bivariate analysis was performed. Comparisons
of continuous variables between groups were carried out using
parametric (t-test) or nonparametric (Mann–Whitney) tests;
associations between categorical variables were analyzed using
the χ2 test and Fisher's exact test, as appropriate; correlations
were assessed using the Pearson or Spearman correlation.
Second, a linearmixed-effectsmodelwasused to evaluate the
associationofDGFwith serial changes of leptin (log-transformed)
and ADPN, controlling for the recipient’s age, gender and BMI.
Third, a receiver operating characteristic (ROC) curve
analysis was performed to assess the utility of the levels of
leptin and ADPN (as well as SCr) in predicting DGF. The
optimal cut-off points were determined.
Statistical analyses were performed using SPSS version
21.0, and a significance level of 0.05 was considered.3. Results
3.1. Study Cohort
The final study cohort included 40 patients. Their demo-
graphic and transplant data are shown in supplementary
material (Table S1).
3.2. Leptin and Adiponectin
The time-course of leptin and ADPN levels during the first
post-transplant week is summarized in Table 1. Compared to
before the transplant, the median leptin levels declined
Table 1 – Time course of the circulating levels of leptin (ln) and adiponectin within the first post-transplantation week.
Before KTx 1st Day ⁎ 2nd Day 4th Day 7th Day
Leptin (ng/mL) Overall 15.9 [8.6–31.7] 8.4 [5.3–20.0] 8.0 [3.4–14.7] 8.4 [0.8–25.2] 10.5 [2.9–25.2]
Median [IQR] DGF 27.4 [12.9–57.7] 12.8 [7.5–22–6] 13.0 [8.7–27.2] 23.1 [1.6–36.7] 16.0 [9.7–26.8]
Non-DGF 11.6 [5.6–41.2] 5.5 [2.2–10.0] 4.2 [2.4–10.0] 0.8 [6-0–15.6] 1.7 [5.3–23.1]
Adiponectin (ng/mL) Overall 226 (72) 119 (35) 114 (33) 139 (35) 165 (29)
Mean (S.D) DGF 250 (80) 110 (39) 105 (37) 130 (39) 157 (32)
Non-DGF 209 (62) 126 (30) 120 (29) 146 (30) 170 (25)
The values shown are the medians and interquartile ranges or the means and standard deviations;
Abbreviations: KTx = kidney transplantation; DGF = delayed graft function; SD = standard deviation.
⁎ 1st day = 8–12 h after surgery.
Fig. 1 – Longitudinal changes of the pre-transplant and
one-week post-transplant circulating levels of leptin and
adiponectin regarding graft function.Evolution of mean and
median values of adiponectin and leptin, respectively,with 95%
confidence intervals; measurements were performed
preoperatively (day 0), and then at first (day 1), second (day 2),
fourth (day 4) and seventh (day 7) days after kidney
transplantation.
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less-pronounced reduction of approximately 34% was ob-
served. With regard to ADPN, compared to before the
transplant, the mean levels of plasma ADPN declined by
approximately 47% at day-1 and 27% at day-7.
As expected, the leptin values were positively correlated
with BMI at all time points, whereas no correlation was found
with ADPN. Levels of leptin, but not ADPN, were significantly
higher in female patients, even after adjustment for BMI, and
correlated positively with the recipients’ ages at all time
points. Neither leptin nor ADPN was significantly correlated
with time on dialysis, age of the transplant donor, HLA
mismatches and cold ischemia time. Additionally, no signif-
icant differences were found in relation to the donor status or
any type or dose of the immunosuppressive drugs used.
3.3. Delayed Graft Function and Acute Rejection
Eighteen (45%) patients had DGF, whereas 22 (55%) patients
experienced prompt graft function. Ten recipients had an
acute rejection episode during their hospitalization for
transplantation, and acute rejection was more frequently
diagnosed in patients with DGF than in those with prompt
graft function (44% vs. 9%, P = 0.025). Only 2 of the non-DGF
patients experienced an acute rejection episode.
3.4. Longitudinal Changes in the Levels of Leptin and
Adiponectin According to Graft Function
Prior to transplantation, no significant differences were found
between patients with DGF or non-DGF with regard to any of
the adipokines evaluated. After transplantation, the mean
levels of leptin were consistently higher in DGF patients at all
time points compared to non-DGF recipients (Table 1 and
Fig. 1), whereas no differences were noted in the mean levels
of ADPN.
A linear mixed-effects model was used to analyze the
longitudinal changes in leptin and ADPN in the two groups of
patients (DGF and non-DGF) by controlling for variables found
to be associated by the bivariate analysis (recipient age,
gender and BMI) and confirmed the independent association
of DGF with the longitudinal changes of leptinemia but not
adiponectinemia. Regarding leptin, the age of the recipients
was no longer statistically significant and was removed from
the final model. The time measurements of leptin, patient
AUC (95% CI) P Value
Day 0 (pre-transplant)
Serum leptin (ng/mL) 0.62 (0.43 -0.81) 0.220
Day 1 (8 to 12 h after surgery)
Serum leptin (ng/mL) 0.76 (0.60-0.92) 0.008
Serum creatinine (mg/dl) 0.72 (0.59-0.90) 0.012
Serum adiponectin (ng/mL) 0.51 (0.31–0.72) 0.676
Leptin reduction rate (%) 
Leptinday 1-day0(%) 0.73 (0.57-0.90) 0.017Δ
Fig. 2 – Receiver operating characteristic curves for the serum
levels of pre-transplant leptin, and leptin, adiponectin and
creatinine measured on the first day after KTx, for predicting
delayed graft function (DGF). The table lists the areas under
the ROC curves of leptin, adiponectin and creatinine for
predicting DGF.Abbreviations: SCr = serum creatinine;
ADPN = adiponectin; AUC = area under the ROC
curve.ΔLeptin day1−day0 = percentage changes in serum leptin
between day-1 and day-0.
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with leptinemia (Table S2). Even after adjusting for recipient
gender and BMI, the DGF remained significantly associated
with the longitudinal changes of leptinemia: the recipients
with prompt graft function presented lower average
leptinemia at all times studied. According to our estimation,
the first mean leptin values after transplantation will be
approximately two times higher in DGF patients when
controlling for recipient gender and BMI. A significant
interaction was observed between the recipient gender and
BMI, whichwas retained in themodel, meaning that the effect
of BMI on leptin changes is different according the gender, i.e.,
the effect of an increase in BMI is more pronounced in males
and attenuated in females.
3.5. Predicting DGF Using Leptin and Adiponectin
Receiver operating characteristic (ROC) analysis was conduct-
ed to evaluate the performance of leptin and ADPN indiscriminating the transplant recipients with DGF. This
analysis showed that leptin at day-1 was moderately accurate
in predicting the need for dialysis within the first week post-
transplant, whereas ADPN was not. The area under the curve
(A.UC) for the prediction of DGF was 0.76 (P = 0.007; 95% CI:
0.60–0.92) for leptin on day-1, which was slightly better than
the diagnostic performance of SCr (AUC = 0.72, P = 0.012; 95%
CI: 0.59–0.90) (Fig. 2). When adjusted for BMI (leptin/BMI ratio),
the performance of one-day leptin in predicting DGF was
similar (AUC = 0.73, P = 0.017; 95% CI: 0.57–0.90). The potential
of pre-transplant leptin levels (day-0) in predicting DGF was
also assessed due to higher levels of leptin in DGF vs. non-DGF
patients before KTx, but this variable performed poorly
having a non-significant AUC of 0.62.
An ROC curve was also created to evaluate the perfor-
mance of the reduction in serum leptin levels between pre-
transplant and day-1 (Δleptin day 1−day0) in predicting DGF and
resulted in an AUC of 0.73 comparable to one-day SCr (Fig. 2).
In analyzing the ROC curve of Δleptin day 1−day0, the optimal
sensitivity and specificity were achieved at a leptin reduction
ratio of 41.7% (sensitivity: 81%; specificity: 62%; positive and
negative predictive values of 68 and 77, respectively).
In analyzing the ROC curve of leptin on day-1, the optimal
sensitivity and specificity were achieved at a leptin concen-
tration of 10.8 ng/mL (sensitivity: 73%; specificity: 77%;
positive and negative predictive values of 76 and 74, respec-
tively). Separate analysis by gender, showed that the perfor-
mance of leptin at day-1 in diagnosing DGF improved
considerably for male gender (AUC = 0.86, P = 0.004; 95% CI:
0.70–1.00), and the optimal sensitivity and specificity were
achieved at a leptin concentration of 6.4 ng/mL (sensitivity:
89%; specificity: 79%; positive and negative predictive values
of 81 and 88, respectively). Due to small number of female
recipients (n = 14), this analysis was not done separately for
female gender.
3.6. Predicting Acute Rejection and Post-Transplant Anti-
HLA Antibodies Using Leptin
The predictive power of serum leptin in acute rejection was
also analyzed, but no significant ability to predict acute
rejection was found at any time-point considered. Pre-
transplant anti-HLA screening was positive in 9 patients
(22.5%) and in 12 patients (30%) during the first year following
KTx; in 2 patients (5.0%) they were detected before transplant
only, in 5 patients (12.5%) after transplant only, and in 7
patients (17.5%) both before and after transplantation. No
significant association between leptin levels and anti-HLA
positivity was showed.4. Discussion
To date, most of the research on leptin and ADPN has been
focused on its association with metabolic and cardiovascular
health. Up to know, no reported study has examined the
clinical utility of these adipokines in the diagnosis of graft
dysfunction after KTx. We studied the performance of leptin
and ADPN levels in predicting DGF using ROC analysis and
compared these results with the routinely used SCr. Leptin
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traditional biomarker SCr in assessing the prognosis of DGF.
Contrary to our expectations, leptinemia did not add sub-
stantially to the early discriminative or predictive power of
SCr for the detection of DGF. Although degradation pathways
of leptin have not been clearly elucidated, it has been
suggested that endogenous leptin is rapidly cleared from
circulation by glomerular filtration and by renal uptake and
degradation [6,25–27]. However, it is possible that other
factors that coexist in the immediate post-transplant period
might stimulate leptin synthesis and delay its elimination.
Inflammation [28] has been implicated in augmenting
leptin secretion. Surgical stress is also associated with an
increase in serum leptin concentration [29,30]. Both of these
conditions concur in KTx. Kidney transplantation is a surgical
procedure that involves an inevitable ischemia-reperfusion
injury with consequent deleterious activation of cellular
oxidases causing oxidative damage, tissue injury and inflam-
mation [31]. Leptin is an acute phase reactant that is involved
in the cytokine network of acute inflammation and stress
response [29]. It is possible that inflammatory cytokines
resulting from the organ transplant process can stimulate
leptin synthesis and attenuate its clearance from circulation,
mainly in recipients with graft dysfunction. This would also
explain why the decrement of plasma leptin concentration in
the immediate post-transplant period did not reach normal
levels in most of patients, even in those with prompt graft
function. At day-7, 64% of our recipients still had levels that
exceeded the upper limit of leptin reference range, or 40%
considering only the recipients with prompt graft function.
Some other studies show the maintenance of elevated serum
concentrations of leptin in KTx recipients [32,33].
This study was designed based upon the assumption that
impaired clearance of leptin (and ADPN) could signal graft
dysfunction earlier than SCr. Of the two adipokines mea-
sured, leptin most closely fulfilled our initial hypothesis.
Adiponectinemia was not significantly higher in recipients
with graft dysfunction andwas not a predictor of DGF. At least
during the first week, graft dysfunction did not reflect
impaired clearance of ADPN, suggesting that factors other
than renal function may be involved. A study from Song and
coworkers [34] demonstrated a decline in circulating ADPN
levels during the initial 72 h after a subtotal nephrectomy in
mice with renal failure, associated to down regulation of
ADPN. Following this reasoning, we can also speculate that
the decrease of circulating ADPN levels observed within the
first week after KTx could be due to two differentmechanisms
according to graft function: enhanced filtration of circulating
ADPN and urinary excretion in prompt graft patients; and
decline in local expression of ADPN in glomerular endotheli-
um as a result of amplified ischemia-reperfusion injury that
usually describes DGF.
Ischemia/reperfusion injury is undoubtedly an important
variable that can influence the outcome of the transplanted
kidney since it is a major risk factor for the development of
DGF and acute rejection [35,36]. In fact, there is an apparent
synergy between the initial injuries of ischemia/reperfusion
and acute graft rejection [37], and because of innate immune
response this deleterious condition can lead to graft dysfunc-
tion [38]. Hence, the immune response against a transplantedorgan may not solely involve a major histocompatibility
complex specific alloimmune response, but in addition, an
immediate nonspecific inflammatory response caused by
ischemia/reperfusion injury [39]. Recent studies highlight
the role of leptin in the immune system [9,20–24], therefore
and beyond DGF we assessed leptin ability to predict acute
rejection and anti-HLA antibodies following KTx. Possibly
because of the small number of patients with acute rejection
and anti-HLA antibodies no significant predictive value was
found. Few studies [22] have addressed the influence of leptin,
or other adipose tissue-derived products, on the allograft
response and outcome, and to the best of our knowledge
none in KTx.
In summary, the findings from the present study clearly
demonstrate the importance of graft function in the clearance
of leptin from the circulation, but not that of ADPN. Graft
function was a stronger determinant of leptinemia, and
the levels of this adipokine slightly outperformed SCr in
predicting DGF. The maintenance of elevated levels of leptin
in KTx and the role of this adipokine in allo-immunity are
some of the questions that arise from this study, showing that
much is still unknown in this field [40].Funding Sources
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